Richard has over 15 years’ experience in working with life science companies, from start-ups to global pharmaceuticals, and is a chartered accountant with a first class degree in Biological Sciences from the University of Durham. Prior to joining Horizon, Richard was Vice President, Finance at CSR plc, a listed hi-tech company with revenues of $1bn.
During his time at CSR, Richard had worldwide responsibility for finance, making significant contributions to the transformational acquisition and integration of NASDAQ listed Zoran Corp., product portfolio management, R&D budgeting and business investment / divestment decisions. Before this, Richard was a Director in Deloitte’s life sciences practice, where he specialized in capital market transactions including IPOs, M&A and fundraising on both the UK and the US markets.
Dr. Darrin Disley, CEO of Horizon, commented: “I’m delighted to welcome Richard to Horizon. As the company continues to expand, it is essential that we maintain a highly experienced executive team with the skills to deliver our growth objectives. Richard’s background is an ideal fit and I very much look forward to working with him.”
Richard commented: “I am extremely pleased to join Horizon at a time of significant opportunity for the company. I look forward to working with a highly talented team of people, to create value and deliver on our strategic ambitions.”
About Horizon Discovery http://www.horizondiscovery.com/
Horizon Discovery Limited (Horizon) is a leading provider of research tools to support translational genomics research and the development of personalized medicines. The Company’s proprietary technology, GENESIS, is the world’s most precise genome editing technology. Using GENESIS, Horizon is able to alter any endogenous gene sequence of a human or mammalian cell-line quickly, reliably and without introducing unwanted and confounding genotypes and/or phenotypes.
Horizon has harnessed GENESIS to create over 400 X-MAN cell lines, the world’s first source of genetically-defined and patient-relevant human cell lines, accurately modeling the disease-causing mutations found in cancer patients. These ‘patients-in-a-test-tube’ are being used by academic and industry leaders to identify the effect of individual genetic mutations on drug activity, patient responsiveness, and resistance, leading to the successful prediction of which patient sub-groups will respond to currently-available and future drug treatments. This enables the design of shorter, more focused, and less expensive clinical trials, ultimately providing the tools to identify the ‘right drugs’ for the ‘right patients’ based upon the unique genetic mutations that define their disease.
In addition to the X-MAN cell lines, Horizon provides GENESIS and X-MAN derived products and services, with industrial application in: bio-pharmaceutical process optimization; clinical diagnostic development; drug discovery & development; and the provision of reference standards for genomic-based clinical research platforms.
GENESIS and X-MAN are registered trademarks of Horizon Discovery Limited.
*******
Contacts:
At Horizon:
Dr. Darrin M Disley
CEO
Tel: +44 (0) 1223 655 587
Email: d.disley@horizondiscovery.com
Media enquiries:
Katie Odgaard
Zyme Communications
Tel: +44 (0)7787 502 947
Email katie.odgaard@zymecommunications.com
Twitter: zymecomms
_______________________________________________